Abstract
A significant proportion of patients with B- and T-cell aggressive non-Hodgkin lymphomas are not cured by standard of care immunochemotherapy, and recent randomised studies have failed to improve outcomes for patients with the most common type, diffuse large B-cell lymphoma. Advances in molecular biology have confirmed aggressive lymphomas to be molecularly heterogeneous, but at present biological knowledge provides limited guidance for clinical practice. This is likely to change as discovery science and targeted therapies in clinical trials begin to identify subtypes that may respond differentially to specific treatments. This chapter reviews the evidence to date and the prospects for changes to clinical practice in the future.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
SEER. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. SEER 2017. https://seer.cancer.gov/statfacts/html/nhl.html. Accessed 2 Apr 2017.
https://www.hmrn.org/statistics/incidence. Accessed 25 Jun 2017.
Feugier P, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117.
Wilson WH, et al. Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: CALGB/Alliance 50303. Blood. 2016;128:469.
d’Amore F, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093–9.
Laport GG. Peripheral T-cell lymphoma: autologous hematopoietic cell transplantation as first-line therapy. Curr Opin Oncol. 2010;22(5):409–13.
Mounier N, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101:4279.
Cunningham D, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381(9880):1817–26.
Récher C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378(9806):1858–67.
Jaeger U, et al. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. Haematologica. 2015;2015:125344.
Leppä S, et al. A phase III study of enzastaurin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment: the prelude trial. Am Soc Hematol. 2013.
Witzig TE, et al. PILLAR-2: a randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL). Proc Am Soc Clin Oncol. 2016.
Vitolo U, et al. Obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma: final results from an open-label, randomized phase 3 study (GOYA). Blood. 2016;128:470.
Thieblemont C, et al. First analysis of an international double-blind randomized phase III study of lenalidomide maintenance in elderly patients with DLBCL treated with R-CHOP in first line, the REMARC study from Lysa. Blood. 2016;128:471.
Davies A, et al. Differential efficacy of bortezomib in subtypes of diffuse large B-cell lymphoma (DLBL): a prospective randomised study stratified by transcriptome profiling: REMODL-B. Hematol Oncol. 2017;35(S2):130–1.
Flinn IW, et al. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Eur J Cancer. 2016;54:11–7.
Wilson WH, et al. The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood. 2012;120(21):686.
Davids MS, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;70:4320.
Bohl SR, et al. Nivolumab induces remission in high-PD-L1 expressing aggressive B-non Hodgkin lymphoma: a single center experience. Blood. 2016;128:1865.
Oki Y, et al. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol. 2015;171(4):463–70.
Horwitz SM, et al. Duvelisib (IPI-145), a phosphoinositide-3-kinase-δ, γ inhibitor, shows activity in patients with relapsed/refractory T-cell lymphoma. Blood. 2014;124:803.
Witzig TE, et al. A comprehensive review of lenalidomide therapy for B- cell non-Hodgkin lymphoma. Ann Oncol. 2015;26:1667.
Witzig TE, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011;25(2):341–7.
Caimi P, et al. A phase 1 study of BET inhibition using RG6146 in relapsed/refractory (R/R) MYC-expressing diffuse large B cell lymphoma (DLBCL). Hematol Oncol. 2017;35(S2):263–5.
Morschhauser F, et al. Interim report from a phase 2 multicenter study of TAZEMETOSTAT, an EZH2 inhibitor, in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. Hematol Oncol. 2017;35:24–5.
Coiffier B, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7(1):11.
Swerdlow SH, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.
Clozel T, et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov. 2013;3:1002.
Morin RD, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole- genome sequencing. Blood. 2013;122:1256.
Park HY, et al. Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma. Oncotarget. 2016;7(52):86433.
Bertier G, Hétu M, Joly Y. Unsolved challenges of clinical whole-exome sequencing: a systematic literature review of end-users’ views. BMC Med Genet. 2016;9(1):52.
Dubois S, et al. Next generation sequencing in diffuse large B cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study. Clin Cancer Res. 2016;22(12):2919–28.
Davies AJ, et al. Differential efficacy of bortezomib in subtypes of diffuse large B-cell lymphoma (dlbl): a prospective randomised study stratified by transcriptome profiling: remodl-B. Hematol Oncol. 2017;35:130–1.
Scott DW, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123(8):1214–7.
Alizadeh AA, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503.
Monti S, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105(5):1851–61.
Moffitt AB, Dave SS. Clinical applications of the genomic landscape of aggressive non-Hodgkin lymphoma. J Clin Oncol. 2017;35(9):955–62.
Iqbal J, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915–23.
Huang Y, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood. 2010;115(6):1226–37.
Manso R, et al. C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas. Haematologica. 2016;101(8):e336.
Ennishi D, et al. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell of origin-specific clinical impact. Blood. 2017;129(20):2760–70.
Barrans S, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360–5.
Zhang HW, et al. Clinical impact of t (14; 18) in diffuse large B-cell lymphoma. Chin J Cancer Res. 2011;23(2):160–4.
Oki Y, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166(6):891–901.
Dunleavy K, et al. Preliminary report of a multicenter prospective phase II study of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphoma. Blood. 2014;124(21):395.
Sehn L, et al. Prognostic impact of BCL2 and MYC expression and translocation in untreated DLBCL: results from the phase III GOYA study. Hematol Oncol. 2017;35(S2):131–3.
Lai C, et al. MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R. Leuk Lymphoma. 2018;59:505–8.
Kühnl A, et al. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: subgroup analysis from the UK NCRI R-CHOP 14 vs 21 trial. Blood. 2015;126:1516.
Roschewski M, et al. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11:12–23.
Staiger AM, et al. Clinical impact of the cell-of-origin classification and the MYC/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2017;35(22):2515–26.
Mareschal S, et al. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica. 2011;96(12):1888–90.
Molina TJ, et al. Young patients with non–germinal center B-cell–like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d’Etudes des Lymphomes de l’Adulte/lymphoma study association phase III trial LNH 03-2B. J Clin Oncol. 2014;32(35):3996–4003.
Davis RE, et al. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194(12):1861–74.
Gang AO, et al. Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56(7):2039–46.
Byrd JC, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.
Wilson WH, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922.
Young RM, et al. CRISPR-CAS9 genetic screens uncover a B cell receptor-MYD88 superpathway in diffuse large B cell lymphoma. Hematol Oncol. 2017;35:25.
Phelan JD, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018;560(7718):387–91.
Hernandez-Ilizaliturri FJ, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell–like than in germinal center B-cell–like phenotype. Cancer. 2011;117(22):5058–66.
Davies A, Caddy J, Maishman T, Barrans S, Mamot C, Care M, Pocock C, Stantion L, Hamid D, Pugh K, Mcmillan A, Fields P, Kruger A, Jack A, Johnson P. A prospective randomised trial of targeted therapy for diffuse large B-cell lymphoma (DLBCL) based upon real-time gene expression profiling: the Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425). ASH Annual Meeting Abstracts. 2015.
Thieblemont CC, et al. First analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide maintenance in elderly patients with DLBCL treated with R-CHOP in first line, the Remarc Study from Lysa. American Society of Hematology, San Diego, CA. 2016.
Thieblemont C, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017;35(22):2473–81.
Young RM, et al. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol. 2015;52(2):77–85.
Golay J, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122(20):3482–91.
Chen L, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111(4):2230–7.
Paul J, et al. Simultaneous inhibition of PI3Kδ and PI3Kα induces ABC-DLBCL regression by blocking BCR-dependent and-independent activation of NF-κB and AKT. Cancer Cell. 2017;31(1):64–78.
Lin T, et al. PILLAR-2: a randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus in poor-risk diffuse large B-cell lymphoma (DLBCL). Proc Am Soc Clin Oncol. 2012.
Carracedo A, Pandolfi P. The PTEN–PI3K pathway: of feedbacks and cross-talks. Oncogene. 2008;27(41):5527–41.
Pfeifer M, et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci. 2013;110(30):12420–5.
Dreyling M, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28(9):2169–78.
Paul J, et al. Simultaneous inhibition of PI3Kδ and PI3Kα induces ABC-DLBCL regression by blocking BCR-dependent and-independent activation of NF-κB and AKT. Cancer Cell. 2017;31(1):64–78.
Erdmann T, et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. 2017;130(3):310–22.
Schmitz R, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–407.
Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679–90.
Cummin TE, Du M, Johnson PW. Genetics of diffuse large B-cell lymphoma. N Engl J Med. 2018;379(5):493–4.
Shaw AT, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–94.
Rimokh R, et al. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (‘Ki-1 lymphoma’). Br J Haematol. 1989;71(1):31–6.
Stein H, et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681–95.
Passerini CG, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase–positive lymphoma patients. J Natl Cancer Inst. 2014;106(2):djt378.
ALEX. randomised phase III ALEX. 2017. http://www.roche.com/media/store/releases/med-cor-2017-04-10.htm.
Béguelin W, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23(5):677–92.
McCabe MT, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492(7427):108–12.
ASH Lymphoma Biology Meeting Report. http://www.epizyme.com/wp-content/uploads/2016/06/EPZM-ASH-L-Data-PR-20160619.pdf.
Assouline SE, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood. 2016;128(2):185–94.
Love C, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44(12):1321–5.
Schmitz R, et al. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med. 2014;4(2):a014282.
Schmitz R, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116–20.
Spender LC, Inman GJ. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt9s lymphoma cells to BH3 mimetics. Mol Cancer Res. 2012;10:347.
Schmitz N, de Leval L. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. Br J Haematol. 2017;176(6):851–66.
Itzykson R, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147–52.
Delarue R, et al. Treatment with hypomethylating agent 5-Azacytidine induces sustained response in angioimmunoblastic T cell lymphomas. Blood. 2016;128:4164.
Reddy A, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481–494.e15.
Sartorius UA, Krammer PH. Upregulation of bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer. 2002;97(5):584–92.
Michels J, et al. MCL-1 dependency of cisplatin-resistant cancer cells. Biochem Pharmacol. 2014;92(1):55–61.
Strasser A. The roles of programmed cell death in tumor development and cancer therapy. Medicographia. 2014;36:311–8.
Roberts AW, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–22.
Choudhary G, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6(1):e1593.
Certo M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9(5):351–65.
Gregory G, et al. CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. Leukemia. 2015;29(6):1437.
Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19(19):5300–9.
Armand P, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733–9.
Ansell SM, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–9.
Green MR, et al. Integrative analysis reveals selective 9p24. 1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268–77.
Shi M, et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol. 2014;38(12):1715.
Chapuy B, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869–81.
Nayak L, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071–3.
Lesokhin AM, et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood. 2014;124(21):291.
Gajewski TF, et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013;25(2):268–76.
Andorsky DJ, et al. Programmed death ligand 1 is expressed by non–Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17(13):4232–44.
Rossille D, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia. 2014;28(12):2367–75.
Shipp MA. Gianni BONADONNA memorial lecture: “genetic signatures and targetable pathways in lymphoid malignancies”. Hematol Oncol. 2017;35:23–4.
Abu-Eid R, et al. Selective inhibition of regulatory T cells by targeting the PI3K–Akt pathway. Cancer Immunol Res. 2014;2(11):1080–9.
Christofides A, et al. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2. Oncotarget. 2016;7(51):85624–40.
Patton DT, et al. Cutting edge: the phosphoinositide 3-kinase p110δ is critical for the function of CD4+ CD25+ Foxp3+ regulatory T cells. J Immunol. 2006;177(10):6598–602.
Gunderson AJ, et al. Bruton tyrosine kinase–dependent immune cell cross-talk drives pancreas cancer. Cancer Discov. 2016;6(3):270–85.
Turaj AH, et al. Antibody tumor targeting is enhanced by CD27 agonists through myeloid recruitment. Cancer Cell. 2017;32(6):777–91.
Roschewski M, et al. Comparative study of circulating tumor DNA and computerized tomography monitoring in untreated diffuse large B-cell lymphoma. Lancet Oncol. 2015;16(5):541.
Kurtz DM, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36(28):2845–53.
Scherer F, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8(364):364ra155.
Rossi D, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017;129(14):1947–57.
Thierry A, et al. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Ann Oncol. 2017;28:2149.
Scherer F, et al. Noninvasive molecular subtyping and risk stratification of DLBCL. Proc Am Soc Clin Oncol. 2016.
Jin MC, et al. Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma. Proc Am Soc Clin Oncol. 2017.
Prasad V. Perspective: the precision-oncology illusion. Nature. 2016;537(7619):S63.
Papadimitrakopoulou V, et al. The BATTLE-2 study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non–small-cell lung cancer. J Clin Oncol. 2016;34(30):3638–47.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Cummin, T.E.C., Cragg, M.S., Friedberg, J.W., Johnson, P.W.M. (2019). Targeted Therapeutics for Lymphoma: Using Biology to Inform Treatment. In: Lenz, G., Salles, G. (eds) Aggressive Lymphomas. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-00362-3_18
Download citation
DOI: https://doi.org/10.1007/978-3-030-00362-3_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-00361-6
Online ISBN: 978-3-030-00362-3
eBook Packages: MedicineMedicine (R0)